Europe – EMA’s Rasi on Genome Editing: Time to Move Forward

For genome editing technologies in drug development, the European Medicines Agency’s (EMA) executive director Guido Rasi said recently that it’s time to not just reflect on the challenges but also to exploit the opportunities to work together with industry and others toward treatments.

The comments, addressed to the EMA Committee for Advanced Therapies (CAT) and the Committee for Human Medicinal Products’ (CHMP) Pharmacogenomics Working Party’s (PGWP) expert meeting on genome editing, come as the number of scientific recommendations on advanced therapy classifications has risen from just a dozen in 2011 to 87 in 2016.

Academics from the Karolinska Institute in Stockholm to the National Center for Tumor Diseases in Heidelberg, Germany discussed the state of the art and outlook for genome editing and technologies, according to a report on the meeting.

“CRISPR offers the possibility for a more rapid and more specific generation of animal models, allowing for effective knockouts in genetically inaccessible models, simultaneous targeting of multiple genes and the possibility of biallelic modification,” Volker Lauschke from the Karolinska Institute said…